1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
James Li
James Li
Articles (481)  | Author's Website |

Stanley Druckenmiller Starts 3 Positions in 3rd Quarter

Guru reports quarterly portfolio

November 15, 2017 | About:

Stanley Druckenmiller (Trades, Portfolio), former partner of George Soros (Trades, Portfolio)’s Quantum Fund, initiated three positions during the third quarter: Citigroup Inc. (NYSE:C), Chubb Ltd. (NYSE:CB) and Celgene Corp. (NASDAQ:CELG).

Citigroup

The Duquesne Capital fund manager invested in 1,095,200 shares of Citigroup for an average price of $68.28 per share. With this transaction, Druckenmiller expanded his portfolio 3.62%.

63ab13229ef062bf7e5ce05cd4f20c55.png

Citigroup’s profitability ranks 4 out of 10, suggesting modest growth potential. The company’s margins and returns are near a 10-year high yet underperform over 55% of global competitors.

2147396140.png

1665234251.png

Citigroup has a negative three-year compound annual growth rate (CAGR) of sales, a severe warning sign according to GuruFocus. The company’s revenues in Corporate / Other declined 55% primarily due to the “continued wind-down of legacy non-core assets.” Despite this, overall company revenues increased 2% year over year.

1491957230.png

Chubb

Druckenmiller added 206,600 shares of Chubb for an average price of $144.66 per share. With this transaction, the guru increased his portfolio 1.34%.

1510779873180.png

Chubb’s profitability rank of 5 suggests the company has satisfactory growth potential. The company said in its third-quarter report that although revenues increased 1% from the prior-year quarter, it still reported a net loss of $70 million due to a $1.893 billion pretax catastrophe loss as a result of the three hurricanes and other natural disasters.

1878177626.png

Celgene

Druckenmiller added 188,100 shares of Celgene for an average price of $135.96 per share. With this transaction, the fund manager increased his portfolio 1.25%.

fe693c45a8abe93240accdb2a66a3929.png

Celgene’s profitability rank of 9 suggests strong short-term growth potential. The company reported net product sales of $3.283 billion for the quarter, up 11% from the prior-year quarter. The strong increase in product sales contributed to a three-year revenue growth of 22.80%, which outperforms 76% of global biotech companies.

670805012.png

Disclosure: I do not have positions in the stocks mentioned.

About the author:

James Li
I am an editorial assistant and researcher at GuruFocus. I have a Master's in Finance from SMU, and I enjoy writing reports on financial trends and investor portfolios. Follow me on Twitter at @JamesLiGuru!

Visit James Li's Website


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by James Li


User Generated Screeners


DswhaleDW BOMB1
UnAmericanOtakuPenny score gods
DswhaleDW BOMB
gluon71gm-june18-profitable-high-grow
Nightdoc2Best Value
alecmazototal yield 3.5%
alecmazoAlec Jun 19 2018
msacaccioStrong Comp Moats
acfinance2018New Filter Value + Growth + Ev
acfinance2018New Filter Value + Growth
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK